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The aim of this review is to examine the current status of gynecological cancer in China focusing on epidemiological 
data. Epidemiological data on gynecological cancer in China is sparse. Therefore, most of the data were estimated via 
extrapolation based on a few available datasets. Cervical cancer is relatively rare and the incidence and mortality rate 
are largely decreasing. However, in young women, the incidence and mortality rates are increasing. The overall and 
age-specific incidence rates of cervical cancer appear to be varied according to geographical areas. The overall 
prevalence rate of human papillomavirus (HPV) in China is similar with other eastern Asian countries, but the 
age-specific HPV prevalence showed sustained high HPV prevalence rates in elderly women. There is not yet an 
established national program for cervical cancer prevention. The incidence rate of corpus and ovarian cancers in China 
slightly increased between 2000 and 2005, but is still lower than Japan or Korea. There is no reliable, national-level 
data on mortality rates of corpus and ovarian cancer in China. Breast cancer is one of the most rapidly increasing 
cancers in China. The increase was sharper in young women than in elderly women. Both increased risk and change of 
population size/structure contributed to the increase of breast cancer.
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INTRODUCTION
Cancer is the major cause of death in developed and develop-
ing countries. In 2002, there were an estimated 10,864,499 
new cancer cases worldwide and 44.9% (N=4,878,952) of 
cases ocurred in Asia. In addition, the mortality rate and the 
number of 5-year prevalent cancer cases were highest in Asia.1 
Therefore, the estimation of cancer burden in Asia would be 
an important issue. 
In spite of geographical proximity, countries in Asia showed 
significant disparities in cancer incidence and mortality. For 
example, worldwide, China and Japan has the highest in-
cidence rates for liver cancer, but the countries in south cen-
tral Asia reported the lowest incidence rate for liver cancer.2 
Therefore, the cancer burden in neighboring countries in Asia 
is worth investigating. Especially, the cancer burden of China 
is noteworthy because of its huge population and dramatic 
change of population and social structures. For example, 
there are about 500,000 new cervical carcinoma cases world-
wide and about 131,500 cases in China (29%).3
The aim of this review was to examine the current status of 
gynecological cancer in China focusing on the epidemiological 
data.
DEMOGRAPHY AND GENERAL HEALTH STATUS 
IN CHINA
China has nearly a quarter of the world population. Recent 
economic, social, and political changes in addition to demo-
graphic transition such as decreasing birth rates and increas-
ingly elderly population are creating new challenges to the 
health care system in China. In addition, rapid economic 
growth resulted in huge inequalities between eastern and 
western China, rich and poor, urban and rural populations.
Over half of the population lives in rural areas. Life expect-
ancy is similar or is slightly lower than that of developed coun-
tries, but infant and under-five year of age mortality rates re-
main high, especially in areas where access to medical services 
is difficult (Table 1).4
Disease burden has largely shifted from communicable to 
non-communicable diseases. For example, the leading causes 
of death in 2002 include cerebrovascular disease, heart disease 
and cancer. However, communicable diseases and malnutrition 
is still a major problem, especially in less developed areas.4
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Table 2. Incidence and mortality rate (per 100,000) of gynecological 
cancer in Eastern Asia
Cancer Country
Incidence Mortality



































































Information on cancer incidence and mortality in China is 
rather sparse. There are several small population-based can-
cer registries located in big cities, relatively developed areas, 
and in some high-risk areas for certain cancer, but national- 
level data is very rare.5 Therefore, most of the cancer-related, 
epidemiological data in China were estimated via extra-
polation based on a few available datasets. The available data-
sets are as follows. 
1) National mortality survey in 1973-1975 and in 1990-1992
2) National mortality reporting system: Center for Health 
Information and Statistics (CHIS)
3) National mortality reporting system: Disease Surveillance 
Points (DSP)
4) Population-based cancer registries
National mortality survey during 1990-1992 included ran-
dom 10% samples of the Chinese population.6 It is the most 
well-formulated dataset to estimate the national-level can-
cer-related mortality, and is used as the basal dataset for many 
epidemiological studies.
CHIS is the most comprehensive dataset on mortality in 
China. It is based on continuing surveillance system involving 
36 cities and 85 counties. CHIS covers a population of about 
100-120 million (10% of the Chinese population), and is used 
by the World Health Organization (WHO) to report mortality 
rates for the urban and rural populations of China.7 However, 
the covered areas of CHIS do not represent a random sample 
of the Chinese population, but are located in the more easily 
accessible cities and counties on the eastern seaboard where 
vital statistics systems are relatively well established.7
DSP is similar to CHIS. However, in a comparison study of 
the mortality rates from CHIS and DSP datasets, authors con-
cluded that the CHIS probably provides a better estimate of 
national cancer mortality rates than the DSP system.6
In a survey of Chinese cancer registration practices in 2002, 
48 population-based cancer registries were identified.8 The 
registries produce statistics on the incidence and outcome of 
cancer in a defined population. However, the registries cov-
ered only 5.7% of the Chinese population and were mostly lo-
cated in the big cities, relatively developed areas, and in some 
high-risk areas for certain cancers. Many of the registries were 
established recently and substantial variations in data quality 
exist.5
GYNAECOLOGICAL CANCER
1. Cervical cancer 
According to the GLOBOCAN 2002 database,9 the incidence 
and mortality rates of cervical cancer in China are lower than 
those of Japan and Korea. Specifically, the age-standardized 
incidence rate of China is only one-third of the Korean rate. 
However, the difference in mortality rate is less pronounced 
than the difference in the incidence rate (Table 2).
There are no direct data on national cervical cancer incidence 
in China. Instead, estimates of cervical cancer incidence were 
calculated using the national mortality survey at 1990-1992, 
CHIS dataset, and population-based cancer registry dataset in 
a study. To explain further, authors estimated the national 
mortality rates by applying the trend of mortality rates calcu-
lated from CHIS dataset to National mortality survey dataset 
at 1990-1992. Then, they estimated the national cancer in-
cidence rates by multiplying the estimated national mortality 
rates by the incidence/mortality ratios, which were extracted 
from five population-based cancer registries (Beijing, Shanghai, 
Wuhan, Qidong, and Jiashan).5
Age-specific and age-standardized incidence rates (per 
100,000) and cumulative risks (0-74 years) of cervical cancer 
in 2000 and 2005 are summarized in Table 3. The cumulative 
risk was the chance by which an individual would develop the 
cancer in question before the age of 75 in the absence of other 
causes of death. Between 2000 and 2005, the overall incidence 
of cervical cancer slightly decreased, but the incidence in the 
young age group increased. Although the incidence of cervical 
J Gynecol Oncol Vol. 20, No. 2:72-76, 2009 Kidong Kim, et al.
74































































































































cancer slightly decreased, the estimated number of cases in-
creased by 13.8% between 2000 and 2005. Most of the in-
crease in number of cases was due to the change of population 
structure and size.5
The incidence rate of cervical cancer appears to be varied ac-
cording to geographical areas. For example, although the na-
tional incidence rate of cervical cancer in China is quite low, 
the incidence rate in specific geographical areas such as Yang-
cheng, Shanxi, was strikingly high (age-standardized rate of 81 
per 100,000 women between 1998-2002).10 In addition, the 
age-specific curves of the incidence rate appear to be varied. 
For example, the estimated, national, age-specific incidence 
rates showed a peak incidence around 50 (Table 3). However, 
data from the five representative population-based cancer reg-
istries showed a second peak of incidence around 80.10
National-level cancer mortality data is sparse in China. 
Specifically, the national mortality survey at 1990-1992 is da-
taset that is about 20 years-old. CHIS is the most compre-
hensive dataset and is based on the ongoing surveillance sys-
tem, but the CHIS cannot be used as the national-level mortal-
ity data because the CHIS is based on non-random sampling. 
Therefore, researchers estimated the national mortality rates 
by applying the trend of mortality rates calculated from CHIS 
dataset to the National mortality survey dataset at 1990- 
1992.11 The investigated or estimated, age-specific and age- 
standardized mortality rates of cervical cancer in 1991, 2000 
and 2005 are summarized in Table 4. Between 1991 and 2005, 
the overall mortality rates of cervical cancer continuously de-
creased, but most of the decrease was due to the marked de-
crease in older age group. In the younger age group, mortality 
rates of cervical cancer increased. With regard to the cause of 
mortality rate change, most of the decrease in mortality rate 
was attributed to the reduced risk for cervical cancer.11 A sim-
ilar trend was observed in another study. Analysis of CHIS da-
taset between 1987 and 1999 showed that the mortality rate 
of cervical cancer decreased. The decreasing trend is sharper 
in urban areas than in rural areas. The decreasing trend is ob-
served only in older age groups (older than 55); increasing 
trend was observed in younger women.7
The data on human papillomavirus (HPV) prevalence was 
available only in limited regions. A population-based preva-
lence survey of HPV infection was conducted in a rural area 
(Xiangyuan, Shanxi province) where a high mortality of cer-
vical cancer was reported. Using Hybrid Capture 2 (Qiagen 
Gaithersburg Inc., Gaithersburg, MD, USA; previously Digene 
Corp.), the overall prevalence of high-risk HPV was 21% 
among women aged 35-50 years.12 Another population-based 
survey conducted in three different areas of China (Yangcheng 
County in Shanxi province, Shenzhen city in Guangdong prov-
ince, Shenyang city in Liaoning province) using polymerase 
chain reaction (PCR) method reported that the overall HPV 
prevalence ranged from 15% to 17%.13
Type distribution of HPV in China showed similar patterns 
with Japan and Korea. The five most common HPV types in 
cervical cancer was 16, 18, 58, 52, and 31; the five most com-
mon HPV types in normal cytology was 16, 58, 52, 18 and 
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Fig. 1. The incidence of gyneco-
logical cancers in Shanghai, China. 
39.10 However, the age-specific HPV prevalence showed a dif-
ferent pattern from other countries. Specifically, in China, the 
HPV prevalence did not decrease with age, and even increased 
in some areas,10,14 although the HPV prevalence was known to 
decrease with age in many developed countries, including 
Japan and Korea.10
In China, there is no established national program for cer-
vical cancer prevention. However, in some areas, opportun-
istic cervical cancer screening for women aged 30-59 years is 
being conducted. Conventional Pap cytology and HPV DNA 
screening tests are available in urban areas, but is not avail-
able in most rural areas. Therefore, since 2006, the central 
government has sponsored a project to provide visual in-
spection with 5% acetic acid stain/visual inspection with 
Lugol’s iodine screening to women in six counties.10
2. Corpus cancer
According to GLOBOCAN 2002 database,9 the incidence 
and mortality rate of corpus cancer in China is lower than 
those of Japan but is similar with those of Korea. Specifically, 
the age-standardized incidence rate of corpus cancer in China 
is only one-third of that in Japan (Table 2).
Like cervical cancer, there is no direct data on national corpus 
cancer incidence in China. Only estimates based on national 
mortality survey at 1990-1992, CHIS dataset, and population- 
based cancer registry dataset are available.5 From 2000 to 2005, 
the incidence of corpus cancer slightly increased. This trend 
was observed in most age groups (Table 3).
We could not find any English-written, estimated or directly 
investigated data on national corpus cancer mortality in 
China. The mortality rate in GLOBOCAN 2002 database was 
based on some population-based cancer registries.
3. Ovarian cancer
According to GLOBOCAN 2002 database,9 the incidence 
and mortality rate of ovarian cancer in China is lower than 
those of Japan and Korea. Specifically, the age-standardized 
incidence rate of ovarian cancer in China is about one-half of 
those in Japan and Korea (Table 2).
Estimates of national incidence rates showed that the in-
cidence of ovarian cancer slightly increased between 2000 and 
2005. This trend was observed in most of age groups (Table 3).5
We could not find any available data on national ovarian cancer 
mortality in China. The mortality rate in GLOBOCAN 2002 da-
tabase was based on some population-based cancer registries.
4. Breast cancer
According to GLOBOCAN 2002 database,9 the incidence 
and mortality rate of breast cancer in China is lower than 
those of Japan but is similar with those of Korea (Table 2).
A study showed that the estimated incidence rate of breast 
cancer markedly increased between 2000 and 2005. The in-
crease was observed in all age groups. The increasing in-
cidence rate was due to the change of risk rather than the 
change of population structure and size.5
The estimated breast cancer mortality rates increased be-
tween 1991 and 2005. The increase was sharper in the young-
er age group than in the older age group (Table 4).11 Similarly, 
in another study, the analysis of CHIS dataset showed that the 
increasing mortality rate of breast cancer was confined to the 
younger age group.7 Both increased risk and change of pop-
ulation structure/size contributed to the increase of mortality 
rates.11
5. Gynecological cancer in Shanghai
Shanghai is one of the biggest cities of China. The incidence 
of breast cancer in 2005 doubled when compared to that of the 
earlier 1980s. The incidence of cervical cancer significantly 
decreased in 1990s, but increased slightly in 2000s because of 
HPV infection in young women. The incidence of ovarian can-
cer still ranks the first among gynecological cancers during the 
past two decades (Fig. 1).
CONCLUSIONS
In China, the incidence rate of cervical cancer is slowly de-
creasing and that of breast cancer is sharply increasing. 
Corpus and ovarian cancer showed a slight increase in 
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incidence. Due to population expansion and increasing pro-
portion of the elderly population, the number of gynecological 
cancers in China will rapidly increase. It is noteworthy that 
cervical and breast cancer increased more in young women 
than in elderly women. 
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